Safety, Tolerability, and Efficacy of MatriPlax in Subjects With Acute Respiratory Distress Syndrome
Status:
Not yet recruiting
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to explore the safety, tolerability, and efficacy in study
intervention, MatriPlax, in subjects with Acute Respiratory Distress Syndrome (ARDS).
MatriPlax contains placenta choriodecidual membrane-derived Mesenchymal Stem Cells (pcMSCs).
Participants will receive two doses of MatriPlax on Day 1 and Day 4 and conduct efficacy and
safety evaluations until 12 months after treatment or withdrawal from the study.